Jeremy A. Squire

TL;DR: A synopsis of the current understanding of the functions of RUNX2 and its potential role in osteosarcoma is provided and directions for future study are suggested.

TL;DR: The analyses show that the RUNX2 interactome may be constitutively activated in osteosarcoma, and that the downstream intracellular pathways are strongly associated with the regulation of osteoblast differentiation and control of cell cycle and apoptosis in ostea.

TL;DR: It is demonstrated that SKY, CGH, and microarray analysis can in combination identify significantly smaller subsets of differentially expressed genes for future studies.

TL;DR: RUNX2 was the only gene of the 16 to show significant overexpression in tumors that had a poor response to chemotherapy relative to good responders, underscore the loss of tumor suppressive pathways and activation of specific oncogenic mechanisms associated with osteosarcoma oncogenesis, while drawing attention to the role of RUNX2 expression as a potential biomarker of chemotherapy failure in osteosarsa.

TL;DR: It is demonstrated that triaging patients by the use of CNAs within pre‐treatment biopsies may allow for better use of systemic therapies to target sub‐clinical metastases or locally recurrent disease and improve clinical outcomes.